乙酰胆碱酯酶抑制剂在阿尔茨海默病治疗中的研究进展
首发时间:2011-12-08
摘要:以进行性记忆减退和认知障碍为特征的阿尔茨海默病(Alzheimer's Disease,AD)是严重威胁老年人生命健康的神经系统退行性疾病。目前临床使用的AD治疗药物主要是针对AD症状治疗的乙酰胆碱酯酶(Acetylcholinesterase, AChE)抑制剂。新近研究发现AChE,尤其是其外周阴离子位点(peripheral anionic sites, PAS),还参与加速Aβ沉积的AD病理过程。同时作用于催化位点和PAS的双位点AChE抑制剂,不仅能提高突触间ACh水平,减轻AD病人的症状;还能抑制Aβ沉积,干预AD的病理过程,产生疾病修饰作用。
For information in English, please click here
Recent research advances on acetylcholinesterase inhibitors in the treatment of Alzheimer's disease
Abstract:Alzheimer's disease (AD), which is characterized by progressive loss of memory and impairment in cognition, is becoming a serious threat to life expectancy for elderly people. Current clinical therapy for AD patients is mainly palliative treatment targeting acetylcholinesterase (AChE). Recently AChE, particularly the peripheral anionic sites (PAS), was indicated to be involved in Aβ peptide aggregation-promoting action. Bivalent AChE inhibitors simultaneously blocking both the catalytic and PAS might not only alleviate the cognitive deficit of AD patients by elevating ACh levels, but also act as disease-modifying agents delaying amyloid plaque formation.
Keywords: Medicinal chemistry Acetylcholinesterase inhibitors Alzhermer's disease Review
论文图表:
引用
No.****
同行评议
共计0人参与
勘误表
乙酰胆碱酯酶抑制剂在阿尔茨海默病治疗中的研究进展
评论
全部评论0/1000